As of May 27
| +1.02 / +15.02%|
The 5 analysts offering 12-month price forecasts for Stemline Therapeutics Inc have a median target of 32.00, with a high estimate of 41.00 and a low estimate of 15.00. The median estimate represents a +309.73% increase from the last price of 7.81.
The current consensus among 6 polled investment analysts is to Buy stock in Stemline Therapeutics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.